ModifiedBlue Cross Blue Shield - TennesseePolicy N/A

General Inflammation Testing (CRP and ESR) Coverage Criteria

Policy governing coverage and limitations for measurement of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) for diagnosing and monitoring inflammatory conditions for Blue Cross Blue Shield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy N/A

Change TypeLanguage clarification and enforcement added

Effective DateN/A

Next Review DateN/A

Key ActionWhen both CRP and ESR are ordered for the same indication, only CRP will be approved; document the diagnosed or suspected condition per Note 1.

SourceLink

POLICY UPDATE CHANGES

Removed the word 'inflammatory' from CC1 and clarified that CRP/ESR measurement meets coverage criteria for the conditions specified in Note 1.

If CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be approved.

Within Note 1's table, added '(e.g., inflammatory bowel disease)' in the 'Frequency of Testing' column for IBS for clarity.

4CPT/HCPCS codes listed

Note 1Coverage enforcement note

no coverage changeNo coverage change

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

literature updatedReferences updated

Coverage Criteria for CRP and ESR

Covered when criteria met / Not covered contexts / Condition-specific preferences

Coverage follows when conditions and context meet the policy's designated indications and limitations:

General coverage rule: Measurement of CRP and/or ESR meets coverage criteria for the conditions specified in Note 1

CRP is preferred when both are ordered; either conventional or high-sensitivity CRP allowed

Not covered contexts: For individuals without a diagnosed inflammatory condition, measurement of ESR does not meet coverage criteria; measurement of CRP and/or ESR during a general exam without abnormal findings does not meet coverage criteria

Condition-specific test preferences: Policy enumerates multiple conditions with specified test preference (CRP, ESR, or both) and in some cases suggested frequency (e.g., osteomyelitis: CRP preferred with serial testing; arthritis: CRP and ESR with monitoring intervals; PJI: CRP and ESR)

See Note 1 table for condition-specific preferences and frequencies

General coverage statement

Covered when testing meets conditions specified in Note 1 and adheres to the policy enforcement on concurrent orders.

Primary coverage rule: Measurement of C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) MEETS COVERAGE CRITERIA for the conditions specified in Note 1.

'Inflammatory' was removed from CC1 to reflect that some Note 1 conditions are noninflammatory; either conventional or high-sensitivity CRP testing are allowed.

Concurrent orders enforcement

Concurrent CRP and ESR orders: If CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be approved.

Enforcement clarification added to Note 1.

Measurement of ESR for individuals without a diagnosed inflammatory condition does not meet coverage criteria. This policy designation applies when there is no documented diagnosis or suspected inflammatory condition at the time of the request; such ESR testing is not eligible for coverage under the policy.]

Measurement of CRP and/or ESR during a general exam without abnormal findings does not meet coverage criteria. Routine screening of asymptomatic individuals during a general examination, without clinical or laboratory evidence suggesting inflammation, is excluded from coverage.]

ref_id_removed_placeholder

No new explicit exclusions were added; the literature review performed during the 06/04/2025 policy update did not necessitate modifications to the policy's coverage criteria. The revision clarified language (removing the word "inflammatory" from CC1) and added enforcement guidance for concurrent ordering, but did not expand or add exclusionary conditions.]

ref":"b0_5"},{

Ordering ESR for individuals without a diagnosed inflammatory condition is considered not meeting coverage criteria (NMN). ESR requests lacking documentation of a diagnosed or suspected inflammatory condition should be considered not medically necessary and are subject to denial.]

ref":"b0_6"},{

No explicit NMN conditions were added or changed in this revision. The 06/04/2025 update clarified wording and enforcement but did not introduce new not-medically-necessary categories.]

ref":"b0_7"},{

Procedure Codes

ESR CPT CodesCPTCovered

85651	Sedimentation rate, erythrocyte; non-automated
85652	Sedimentation rate, erythrocyte; automated

CRP CPT CodesCPTCovered

86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

Provider Actions, Documentation, and Authorization

Documentation Required

Documentation of diagnosis / suspected condition required

Coverage of CRP and ESR is determined by the diagnosed or suspected condition. Documentation submitted with test orders must clearly state the diagnosis or suspected condition that justifies CRP and/or ESR testing. Coverage depends on the individual's benefit coverage at the time of the request.

Ensure the clinical diagnosis or suspected condition is documented on the order or in the medical record.
Specify whether CRP (including high-sensitivity CRP) or ESR is being requested and reference the condition listed in Note 1 that supports testing.
If both CRP and ESR are ordered for a condition where only one is allowed, indicate the clinical rationale — operationally only CRP will be approved.
For individuals without a diagnosed or suspected inflammatory condition, testing may be denied as not meeting coverage criteria.

Prior Authorization

Test preference and concurrent ordering

Background and Rationale

Acute phase reactants such as serum C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are laboratory measures used to monitor inflammation in conditions such as arthritis, lupus, and infection. Either conventional or high‑sensitivity CRP testing is allowed, and when both CRP and ESR are ordered concurrently for the same indication, CRP is preferred and will be approved in place of ESR where applicable.]

ref":"b3_0"}]}{

Key Definitions

inv-20: Acute phase reactants / CRP definition

TermAcute phase reactants / C-reactive protein (CRP)

DefinitionProteins released during the acute-phase response to inflammation; serum CRP is used to monitor inflammatory activity.

Allowed assay typesEither conventional CRP or high-sensitivity (hsCRP) testing are permitted.

inv-21: ESR definition

TermErythrocyte sedimentation rate (ESR)

DefinitionA simple laboratory technique that measures the rate at which erythrocytes settle; used as a nonspecific marker of inflammation.

Clinical use

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyGeneral Inflammation Testing (CRP and ESR) Coverage Criteria

Policy CodePolicy N/A

Change TypeLanguage clarification and enforcement added

Effective DateN/A

Next Review DateN/A

Key ActionWhen both CRP and ESR are ordered for the same indication, only CRP will be approved; document the diagnosed or suspected condition per Note 1.

SourceLink

On This Page

When either CRP or ESR is an allowed test for the diagnosed or suspected condition (per Note 1), CRP is the preferred biomarker. If both tests are ordered concurrently for such a condition, operational enforcement will approve CRP and may deny ESR.

Preferred test: CRP (conventional or high-sensitivity) when either CRP or ESR is allowed.
Concurrent orders for CRP + ESR where only one is permitted: ESR may be denied; CRP will be approved.
Orders for ESR or CRP without documentation of an appropriate diagnosed or suspected condition may be denied.

Denial Risk

Denial triggers and coverage dependency

Coverage determinations are made in context of the member's benefit plan at the time of service. Measurement of CRP and/or ESR meets coverage criteria only for the conditions specified in Note 1. Measurement of ESR (or CRP) during a general exam without abnormal findings does not meet coverage criteria.

Do not order CRP or ESR solely as part of a general exam without abnormal findings — such testing does not meet coverage criteria.
For members without a diagnosed inflammatory condition, ESR testing does not meet coverage criteria.
Ensure medical records support the clinical indication listed in Note 1 at the time of the request.

Note

Prior authorization and operational enforcement

Operational notes for ordering and authorization: when both CRP and ESR are requested for the same clinical encounter and the indication allows only one, the CRP result will be accepted and the ESR may be administratively denied. Prior authorization processes were not changed; this policy clarifies acceptance of CRP or ESR per Note 1 and the enforcement approach when both are ordered.

No additional prior authorization modifications were required as a result of the reviewed literature.
If both tests are ordered where policy allows only one, expect operational enforcement favoring CRP.
Document the clinical reason if both tests are clinically necessary; lack of supporting documentation may result in denial of ESR.

May be used alongside CRP to assess or monitor inflammatory conditions.

inv-22: CRP/ESR testing definition

Combined testing ruleMeasurement of CRP and/or ESR MEETS COVERAGE CRITERIA for the conditions specified in Note 1.

Test preference when both orderedIf CRP and ESR are ordered at the same time for a condition where CRP or ESR are allowed, only CRP will be approved (CRP is the preferred biomarker).

PurposeCRP and ESR are biomarkers used to differentiate inflammatory from noninflammatory conditions and to monitor inflammatory activity.